Log in

ASX:AVHAvita Medical Stock Price, Forecast & News

+0.04 (+8.70 %)
(As of 05/13/2020)
Today's Range
Now: A$0.50
50-Day Range
MA: A$0.48
52-Week Range
Now: A$0.50
Volume27.28 million shs
Average VolumeN/A
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices



Sales & Book Value

Annual Sales$495,188.00
Cash FlowA$0.01 per share
Book ValueA$0.00 per share



Outstanding Shares2,117,469,952
Market Cap$1.06 billion
Next Earnings DateN/A

Receive AVH News and Ratings via Email

Sign-up to receive the latest news and ratings for AVH and its competitors with MarketBeat's FREE daily newsletter.

Avita Medical (ASX:AVH) Frequently Asked Questions

How has Avita Medical's stock been impacted by COVID-19 (Coronavirus)?

Avita Medical's stock was trading at A$0.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AVH stock has increased by 6.4% and is now trading at A$0.50. View which stocks have been most impacted by Coronavirus.

How were Avita Medical's earnings last quarter?

Avita Medical Ltd (ASX:AVH) announced its quarterly earnings data on Thursday, February, 28th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. View Avita Medical's earnings history.

Has Avita Medical been receiving favorable news coverage?

Press coverage about AVH stock has been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avita Medical earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAvita Medical.

Who are some of Avita Medical's key competitors?

What other stocks do shareholders of Avita Medical own?

Who are Avita Medical's key executives?

Avita Medical's management team includes the following people:
  • Dr. Michael S. Perry, CEO & Director (Age 60)
  • Mr. Dale A. Sander, Chief Financial Officer (Age 59)
  • Mr. Timothy Rooney, Chief Admin. Officer
  • Mr. Andrew Quick, Sr. VP of Clinical Devel.
  • Ms. Erin Liberto, Chief Commercial Officer

What is Avita Medical's stock symbol?

Avita Medical trades on the ASX under the ticker symbol "AVH."

What is Avita Medical's stock price today?

One share of AVH stock can currently be purchased for approximately A$0.50.

How big of a company is Avita Medical?

Avita Medical has a market capitalization of $1.06 billion and generates $495,188.00 in revenue each year. Avita Medical employs 55 workers across the globe.

What is Avita Medical's official website?

The official website for Avita Medical is www.avitamedical.com.

How can I contact Avita Medical?

The company can be reached via phone at 661-367-9170.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.